stockrow
Friday 6 November 2026
Export RNLXY’s income statement to Excel — free account
Renalytix plc - Sponsored ADR
RNLXY Healthcare Health Information Services
Renalytix plc - Sponsored ADR’s revenue for fiscal 2025 (year ended June 2025) was $3.0 million, up 30.4% from fiscal 2024.
3.70
0.09
−2.37%
Follow RNLXY
Alert me
| Jun '25 | Dec '24 | Sep '24 | Jun '24 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | 4.68 | 5.91 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (2.88) | (1.81) | |
P/B ratio |
— | — | 0.00 | 0.00 | |
Price to Tangible BV |
— | — | 0.00 | 0.00 | |
EV/Sales |
— | — | 6.03 | 5.43 | |
EV/EBITDA |
— | — | 0.00 | 0.00 | |
EV/Operating CF |
— | — | (0.59) | (0.42) | |
EV/FCF |
— | — | (0.58) | (0.41) | |
Quick Ratio |
— | 2.22 | 0.15 | 0.52 | |
Current Ratio |
— | 2.43 | 0.24 | 0.58 | |
Net Debt/EBITDA |
— | 0.00 | (0.79) | 0.22 | |
Debt/Assets |
0.00% | 71.72% | 85.52% | 53.94% | |
Debt/Equity |
— | (5.99) | (0.36) | (0.55) | |
Asset Turnover |
0.00 | 0.00 | 0.19 | 0.12 | |
Operating CF/Net income |
— | 0.00 | 0.81 | 1.06 | |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | — | 176.44% | 177.89% | |
Selling, General and Administrative Expense of Revenue |
— | — | 626.63% | 2,587.60% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
— | 0.00% | 48.66% | (31.99%) | |
Graham Net Nets |
— | — | (1.20) | (0.66) | |
Graham Number |
— | — | 45.54 | 43.60 | |
Earnings Yield |
— | — | (329.20%) | (324.37%) | |
Free Cash Flow Yield |
— | — | (221.67%) | (222.12%) | |
Revenue per Share |
— | — | 0.25 | 0.28 | |
Operating CF per Share |
— | 0.00 | (1.81) | (3.47) | |
Capex per Share |
— | — | 0.00 | 0.00 | |
Free Cash Flow per Share |
— | 0.00 | (1.81) | (3.47) | |
Cash per Share |
— | 0.00 | 0.43 | 2.49 | |
Shareholders Equity per Share |
— | 0.00 | (5.35) | (3.62) | |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | |
Book value per Share |
— | 0.00 | (5.35) | (3.62) | |
Free Cash Flow |
— | (6.50) | (3.84) | (7.52) | |
Working Capital |
— | 6.59 | (9.13) | (5.00) | |
Capital Expenditures |
— | — | — | 0.00 | |
Net Current Asset Value |
— | (1.62) | (13.23) | (9.03) | |
EV/EBIT |
— | — | 0.00 | 0.00 | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 0.94 | 0.96 | 0.74 | |
Average Payables |
— | 3.71 | 4.48 | 5.27 | |
Average Inventory |
— | 0.42 | — | 0.20 | |
Average Assets |
4.38 | 11.36 | 12.17 | 19.30 | |
Average Common Equity |
— | (4.66) | (6.40) | (1.02) |
Columns are period end dates · fundamentals updated 26 Oct 2026